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BACKGROUND: Growth differentiation factor 15 (GDF15) belongs to the transforming growth factor beta superfamily and has been
associated with activation of the p53 pathway in human cancer. The aim of this study was to assess the prognostic value of GDF15 in
patients with colorectal cancer (CRC).
METHODS: Immunohistochemistry and tissue microarrays were used to analyse GDF15 protein expression in 320 patients with CRC.
In a subgroup of 60 patients, the level of GDF15 protein in plasma was also measured using a solid-phase proximity ligation assay.
RESULTS: Patients with CRC with moderate to high intensity of GDF15 immunostaining had a higher recurrence rate compared with
patients with no or low intensity in all stages (stages I–III) (HR, 3.9; 95% CI, 1.16–13.15) and in stage III (HR, 10.32; 95% CI,
1.15–92.51). Patients with high plasma levels of GDF15 had statistically shorter time to recurrence (P¼0.041) and reduced overall
survival (P¼0.002).
CONCLUSION: Growth differentiation factor 15 serves as a negative prognostic marker in CRC. High expression of GDF15 in tumour
tissue and high plasma levels correlate with an increased risk of recurrence and reduced overall survival.
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Colorectal cancer (CRC) is the third most common cancer in the
Western world. Globally, the age-standardised incidence rate for
CRC is 20.1 per 100000 males and 14.6 per 100000 females (Parkin
et al, 2005). Surgery is the most important treatment, but a
substantial number of patients will get a recurrence, a risk being
stage-dependent. The use of adjuvant treatment with 5-fluorouracil
(5-FU) and folinic acid, after curative surgical resection for CRC,
reduces the relative risk of recurrence by 30–35% and the addition
of oxaliplatin reduces it even further (about 15–20%) (Ragnhammar
et al, 2001; Andre et al, 2004). The relative risk reduction appears to
be relatively independent of stage (Gill et al, 2004). In patients with
node-positive disease (stage III), the gains translate into meaningful
improvements in overall survival, but in patients with node-negative
disease (stage II), the survival gain is only in the order of a few
percent (Gray et al, 2007). It is not clear which all patients in stages
II and III will benefit from adjuvant treatment and which in
all patients, chemotherapeutic drug/s will be most effective.
Consequently, there is a need for individualised therapy in patients
curatively operated for CRC stages II and III.
Several prognostic and predictive markers have been identified,
although very few of them are currently used in clinical practice.
Microsatellite instability (MSI) is one prognostic factor in use
for recurrence and overall survival in patients with CRC stages II
and III (Watanabe et al, 2001; Popat et al., 2005). Other identified
prognostic markers in primary disease are thymidylate synthase
and loss of heterozygosity of 18q, but these are currently not
used in clinical practice. No predictive marker for response to
adjuvant therapy has yet reached clinical use, although some
studies show that MSI tumours do not adequately respond to 5-FU
(Hemminki et al, 2000; Elsaleh et al, 2001; Jover et al, 2006;
Ohrling et al, 2010). Mutations in KRAS are clinically used as a
predictor for poor response to treatment with EGFR-directed
antibodies in patients with metastatic CRC (Amado et al, 2008;
Karapetis et al, 2008).
Growth differentiation factor 15 (GDF15) belongs to the
transforming growth factor beta superfamily and has a role in
regulating inflammatory and apoptotic pathways in injured tissues
and during disease processes. Under normal conditions, the
placenta is the only tissue that expresses GDF15 in significant
amounts; however, small amounts of GDF15 mRNA can be
detected in a few other tissues, including the kidneys, pancreas,
prostate and colon (Fairlie et al, 1999). Growth differentiation
factor 15, also known as PTGF-b, TGF-PL or MIC-1, has been
hypothesised to serve as a secreted biomarker for activation of the
p53 pathway in human cancer (Seetoo et al, 2003; Koopmann et al,
2004; Weber et al, 2005; de Wit et al, 2005; Brown et al, 2006), and
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sin CRC MIC-1, serum levels and genotype were associated with
decreased overall survival and extent of disease (Brown et al, 2003;
Xue et al, 2010). Immunohistochemical analysis of GDF15
expression in CRC has also been associated with lymph node
metastasis (Xue et al, 2010).
Our aim was to further validate the prognostic value of
immunohistochemical GDF15 expression and GDF15 levels in
plasma in a defined cohort of patients operated for CRC.
PATIENTS AND METHODS
Patients
A population-based cohort of 320 patients with CRC, treated
between August 2000 and December 2003 at the Central district
Hospital in Va ¨stera ˚s, were prospectively included to participate in
the study after giving informed consent. The median follow-up
time was 6 years (8–10) in surviving patients. Information about
tumour size, grade, stage and location, neurovascular tumour
infiltration, lymph node involvement and mucinous component
were obtained from the pathology records, and had, thus, been
assessed by different pathologists. Selection of tumour areas used
for tissue microarrays (TMAs) was made by one single pathologist
(KJ). Information about cancer recurrence, cause of death and the
use of neo-adjuvant/adjuvant treatment was obtained from
surgical and oncology records and by matching with the Clinical
Database for Colorectal cancer held at the Regional Oncologic
Center in Uppsala/O ¨rebro region.
TMA construction
All cases were histopathologically re-evaluated on H&E stained
tumour specimens by one pathologist (KJ), and areas representative
of normal mucosa, invasive tumour, lymph node metastases and,
when present, adenomatous tissue were selected. A manual arraying
device (MTA-1, Beecher Instruments Inc., Sun Prairie, WI, USA) was
used for extraction of five 1.0-mm cores from each case; two from the
invasive tumour, one from normal mucosa, one from adenomatous
mucosa and one from a selected lymph node metastasis.
Immunohistochemistry and annotation
Immunohistochemistry was performed on 4mm TMA sections
using HPA011191 (Atlas Antibodies, Stockholm, Sweden) as
primary antibody to detect GDF15. Automated immunohisto-
chemistry (Autostainer 480, Lab Vision, Fremont, CA, USA) was
performed as previously described (Paavilainen et al, 2010).
Immunohistochemically stained TMA sections were scanned in
high-resolution scanners (ScanScope T2, Aperio Technologies,
Vista, CA, USA) and separated into individual spot images
representing different cores in the TMAs. The annotation process
included estimation of the intensity of immunoreactivity for
GDF15 (negative (0), weak (1), moderate (2), or strong, (3) and
fraction (%) of GDF15-positive cells (o1% (0), 1–24% (1), 25–
75% (2), or 475% (3)) (Figure 1). Tumours with no (0) or low (1)
intensity and no (0) or low (1) fraction of GDF15 expression were
allocated to one group and tumours with moderate (2) or high (3)
intensity and moderate (2) and high (3) fraction of GDF15
expression were allocated into a second group.
Figure 1 These images represent the four levels of the intensity of immunoreactivity, resulting from immunostaining with GDF15 antibody on primary
colorectal cancer tissues. Negative (A), weak (B), moderate (C) and strong intensity staining (D). Images with immunostaining present had 25–75% fraction
of positive cells.
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Pre-surgery EDTA plasma was analysed for GDF15 abundance.
Patients initially included in the study were selected for GDF15
plasma analyses. The aim was to include 10 patients in each group
after stratifying both for recurrence and stage. However, because of
limitations in the number of cases in our cohort (i.e., recurrence in
stage I) and limitations in availability of plasma samples, only nine
patients with stage I (one recurrence), approximately 10 patients
with and without recurrence from stages II and III, respectively,
and 8 patients with stage IV were selected from the whole cohort.
GDF15 was analysed by using SP-PLA (Darmanis et al, 2010). The
protocol was modified to facilitate multiplex detection of various
analytes, including GDF15, according to a method currently
prepared for publication.
Statistical analyses
For categorical data, the w
2-test was performed. All P-values were
two sided, and statistical significance was set at Po0.05. Wilcoxon
matched-paired sign test was used to compare GDF15 staining
intensity and fraction between normal mucosa and tumour.
Kruskal–Wallis ANOVA test was used to compare the median
values of GDF15 plasma levels between different disease stages and
the Mann–Whitney U-test was used to compare the median values
of GDF15 plasma levels within each disease stage. The Kaplan–
Meier method was used for survival analyses and comparison of
strata performed by the log-rank test. Cox proportional multi-
variate analyses were performed to evaluate the statistical
significance and independence of intensity and fraction of
GDF15 expression and only variables with a P-value o0.10 in
univariate analysis were included in the multivariate analyses.
Patients without known metastases at the time of surgery and
microscopically free resection margin (R0) were considered to be
curatively operated. Overall survival was measured from the time
of surgery to the time of death, irrespective of cause. Time to
recurrence was calculated as time to any event related to the same
cancer (Punt et al, 2007). Deaths from other cancers (n¼4), non-
cancer-related deaths (n¼65), treatment-related deaths (n¼6)
and loss to follow-up (n¼1) were censored. Second primary same
cancers (n¼4) and other primary cancers (n¼22) were ignored.
All observations were censored at the end of the study period
(15 April 2010). Data were analysed using STATISTICA software
(version 7.1, StatSoft Inc., Tulsa, OK, USA).
Ethical approval (no 00-001) was obtained from the Ethics
Committee at Uppsala University, Uppsala, Sweden.
RESULTS
Identification of GDF15 as a potential prognostic marker
The GDF15 antibody HPA011191 was generated within the Swedish
Human Protein Atlas project (http://www.proteinatlas.org; http://
www.proteinatlas.org/ENSG00000130513/antibody) (Uhlen et al,
2005). The antibody was validated by protein epitope signature
tag array analysis with high specificity and a supportive pattern
was seen by immunohistochemistry, consistent with experimental
and/or bioinformatic data. In addition, western blotting revealed a
single band corresponding to the predicted size of 34kDa. Protein
profiling of GDF15 expression was performed using HPA011191 on
TMAs containing normal tissues from 140 different individuals,
cancer tissues from 216 patients and 47 cell lines (Ponten et al,
2008). GDF15 was selectively expressed with strong cytoplasmic
immunostaining in trophoblastic cells from the placenta, and only
Table 1 Expression of GDF15 in normal tissue adjacent to an invasive
tumour (a) and invasive tumours (b)
GDF15 intensity of
immunoreactivity staining
GDF15 fraction of GDF15
stained positive cells 0 1 2 3 Total
(a) Normal tissue
07 0 1 0 1 4 3 9 7
10 1 2 4 7
20 4 1 1 1 1 6
30 2 8 0 1 0
Total 70 17 35 8 130
(b) Tumour tissue
0 29 18 81 35 163
1 0 4 45 54 103
20 0 3 1 1 7 4 8
30 0 3 0 3
Total 29 22 160 106 317
Abbreviation: GDF15¼growth differentiation factor 15. The intensity of immuno-
reactivity for GDF15 (negative (0), weak (1), moderate (2), or strong (3)) and
fraction of positive cells (o1% (0), 1–25% (1)), 25–75% (2), or 475% (3)) are
presented in the tables.
Table 2 Clinical and pathological characteristics in association with the
distribution of fraction of positive cells and intensity of immunoreactivity for
GDF15 analysed by immunohistochemistry in 320 patients with colorectal
cancer
GDF15
Fraction of positive
cells (%)
Intensity of
immunoreactivity (%)
No or low
(0–1)
Moderate or
high (2–3)
No or low
(0–1)
Moderate or
high (2–3)
Sex
Male 28 (17%) 132 (83%) 130 (81%) 30 (19%)
Female 23 (15%) 136 (85%) 136 (87%) 21 (13%)
Average age
(range) in years
70 (48–88) 71 (35–94) 71 (39–91) 72 (36–94)
Stage
I 33 (75%) 11 (25%) 9 (20%) 35 (80%)
II 114 (86%) 18 (14%) 17 (13%) 115 (87%)
III 81 (81%) 19 (19%) 16 (16%) 84 (84%)
IV 37 (93%) 3 (7%) 9 (23%) 31 (77%)
Differentiation
Well 8 (89%) 1 (11%) 3 (33%) 6 (67%)
Moderate 199 (83%) 41 (17%) 34 (14%) 206 (86%)
Poor 59 (87%) 9 (13%) 14 (21%) 54 (79%)
Mucinous features
o50% 233 (85%) 41 (15%) 46 (17%) 228 (83%)
450% 33 (77%) 10 (23%) 5 (12%) 38 (88%)
Vascular invasion
Yes 33 (83%) 7 (17%) 11 (28%) 29 (72%)
No 233 (84%) 44 (16%) 40 (14%) 237 (86%)*
Neural invasion
Yes 6 (75%) 2 (25%) 3 (38%) 5 (62%)
No 260 (84%) 49 (16%) 48 (16%) 261 (84%)
Localisation
Rectum 83 (78%) 23 (22%) 19 (18%) 87 (82%)
Colon 183 (87%) 28 (13%) 32 (15%) 179 (85%)
Abbreviation: GDF15¼growth differentiation factor 15. *Po0.05 with 95%
confidence interval.
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types, including the colon and prostate. A differential expression
pattern was found in cancer tissues representing several forms of
cancer, within CRC ranging from negative tumours to tumours
with strong GDF15 expression.
Immunohistochemical analyses
The intensity of immunoreactivity (Po0.001) was higher in
tumour tissue than in normal colon mucosa, but no difference in
the fraction of positive cells was observed (P¼0.19) (Table 1).
In addition, no difference in fraction (P¼0.36) or intensity
(P¼0.56) of GDF15 expression between adenoma and normal
tissue was observed, however, the number of patients with
adenomas in the cohort was low (n¼9). Tumours expressing
moderate or high intensity of GDF15 were less likely to have
vascular invasion (P¼0.036). No other histopathological or
clinical parameters were correlated with the intensity or fraction
of GDF15 in the tumour (Table 2).
Survival analyses
Patients curatively treated for CRC in stages I–III or in stage III
with moderate to high intensity of immunoreactivity for GDF15
had a higher recurrence rate and shorter time to recurrence
compared with patients with no or low intensity for GDF15
(Figures 2A and B). These differences were statistically significant
in multivariate analysis (stages I–III, (HR, 3.9; 95% CI,
Cumulative proportion surviving (Kaplan–Meier)
Complete   Censored
0123456789 1 0 1 1
Time
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
No or low GDF15 intensity staining (n=41)
 Moderate or high GDF15 intensity staining (n=233)
(HR; 3.9; 95% CI, 1.16–13.15)
Number at risk  
In GDF15 0–1   41  38  37  34 32  27  25  19 9 1 
In GDF15 2–3   233  215 202 184  167 150 135  87  32  0 
Cumulative proportion surviving (Kaplan–Meier)
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 No or low GDF15 intensity staining (n=15)
 Moderate or high GDF15 intensity staining (n=83)
(HR, 10.32; 95% CI, 1.15–92.51) 
Number at risk  
In GDF15 0–1  15  14  14  13  13 11 9 7 3 1 
In GDF15 2–3  83  68 53 45 40  35 34 20  8  0 
A
B
Figure 2 Time to recurrence according to the intensity of immunoreactivity of GDF15 in the primary invasive tumour tissue in patients curatively
operated for CRC stages I–III (A) and III (B).
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Neither the intensity nor the fraction of GDF15 had any influence
on overall survival in the cohort.
In 42 out of 100 curatively treated patients with stage III disease,
immunohistochemical staining for GDF15 could be assessed in
lymph node metastases. The intensity of GDF15 staining was
higher in the primary cancer compared with the lymph node
metastases (P¼0.035). Patients with moderate to high intensity of
immunoreactivity of GDF15 in the lymph node metastases did not
have any higher risk of recurrence compared with patients with no
to low intensity of GDF15 (P¼0.08). However, when the intensity
of GDF15 in lymph node metastases was stratified to no to
moderate vs high, high expression was associated with increased
risk for recurrences in stage III CRC (HR 1.78; 95% CI, 1.59–38.03)
in a multivariate Cox regression model including gender, heredity
for CRC, N stage, CEA and neural invasion.
Comparison with CEA
Low intensity of immunoreactivity in the primary tumour was
associated with low levels of CEA (Figure 3A). When analysing
patients with stage III disease, in which serum CEA was available
for 91 of 100 patients, a decreased risk of recurrence was observed
with low intensity of immunoreactivity for GDF 15 in the primary
tumour independent of CEA level. In patients with high intensity
of immunoreactivity for GDF15 and CEA46ngml
 1, an increased
risk of recurrence was observed (HR 2.33; 95% CI, 1.15–4.42). This
remained statistically significant in the multivariate analysis
(including gender, heredity for CRC, N stage and neural invasion)
(Figure 3B).
Plasma analyses of GDF15
Plasma levels of GDF15 were available for 57 patients, 28 without
and 21 with recurrent disease and 8 with stage IV disease. A
nonsignificant trend of elevated plasma levels of GDF15 was
observed in tumours with increasing intensity (P¼0.148) and
fraction (P¼0.326) of GDF15 expression as assessed by immuno-
histochemistry (Figures 4A and B). Patients with high plasma
levels of GDF15 had a shorter time to recurrence (P¼0.041) and a
shorter overall survival (P¼0.002) in the univariate analysis, and
this remained significant for overall survival in multivariate
analysis (HR 2.11; 95% CI, 1.04–4.28) (Figure 4C).
There was no significant difference in median GDF15 plasma
levels between patients with or without recurrence when compar-
ing all stages; however, in patients with stage III, a trend of a
higher median plasma level of GDF15 was observed compared with
patients in stage III without recurrence (P¼0.072) (Table 4).
Comparison between plasma levels of GDF15 and CEA
The GDF15 plasma levels gradually increased with disease stage,
whereas the CEA levels were low in stages I–III and markedly
increased in stage IV (Figure 5). There was a weak correlation
between the GDF15 plasma levels and CEA in the whole cohort
(Po0.001; r¼0.49), however, a stronger correlation was observed
in stage IV (P¼0.045; r¼0.72).
Table 3 Results from the univariate and multivariate Cox regression
analyses estimating the effect of the intensity, fraction of GDF15 expression
on time to recurrence in patients curatively operated for CRC in stages I–III
(n¼277) and in stage II (n¼131) and stage III (n¼100) separately
Univariate
analyses
Multivariate
analyses
Time to
Recurrence P-value
HR
(95% CI) P-value
HR
(95% CI)
Intensity moderate and strong vs no and weak staining
Stage II 0.84 1.17 (0.27–5.08)
Stage III 0.003 11.02 (1.32–92.35) 0.003 10.32 (1.15–92.51)
Stages I–III 0.012 3.83 (1.17–12.5) 0.012 3.9 (1.16–13.15)
Fraction 25–75% and 475% vs o1% and 1–25%
Stage II 0.6 0.7 (0.16–3.03)
Stage III 0.28 1.51 (0.73–3.11)
Stages I–III 0.7 1.13 (0.6–2.14)
Abbreviations: CI¼confidence interval; CRC¼colorectal cancer; GDF15¼growth
differentiation factor 15; HR¼hazards ratio. In the multivariate analyses adjustment
for CEA, sex, location, stage, vascular or neural invasion and adjuvant or neoadjuvant
therapy was performed.
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Figure 3 Curatively treated patients with colorectal cancer stages I–III
(n¼277). Box plot revealing higher CEA levels in those with increased
expression of GDF15 defined as intensity of immunoreactivity (1)
compared with low expression (0) (A). Time to recurrence in curatively
treated patients with CRC and stage III divided into subgroups according to
intensity of immunoreactivity for GDF15 and preoperative CEA levels.
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In this study, we demonstrated a higher recurrence rate in patients
curatively operated for CRC stages I–III with moderate or high
intensity of GDF15 expression, compared with tumours with no or
low intensity of GDF15 expression. This was also demonstrated
separately for patients with stage III disease, but not for patients
with stage II disease.
Our data are consistent with previous findings by Xue et al
(2010) who investigated the expression of GDF15 in 69 CRC cases
by immunohistochemistry. They demonstrated not only an
association between upregulation of GDF15 and development of
metastases but also, different from our study, an increased
immunohistochemical GDF15 expression in stages III and IV
compared with stages I and II. However, unlike our study, the
study by Xue et al (2010) used a combined score to quantify
the intensity and fraction of GDF15 immunostaining, thus, limiting
further comparisons between the two studies.
Brown et al (2003) demonstrated an association between high
GDF15 blood levels, presence of metastatic disease and an elevated
risk of death. In our study, we observed that the risk of death was
more than two times higher (HR 2.2; 95% CI, 1.3–3.7) in patients
with elevated GDF15 plasma levels (4116pM per 5ml), which can
be compared with the results documented on patients with
elevated GDF15 serum levels (41150pgml
 1) by Brown et al
(2003) (OR 2.11; 95% CI, 1.04–4.28). In our study, the plasma levels
of GDF15 were not significantly different between patients with or
without recurrence in stages I–III, even though there was a trend of
a higher plasma levels in patients with recurrence in stage III.
The presence of vascular invasion is known to be an
independent prognostic factor for both colon (Shepherd et al,
1989; Petersen et al, 2002) and rectal cancer (Talbot et al, 1980;
Willett et al, 1999; Smith et al, 2008). A study by Petersen et al
(2002) even proposed that the presence of vascular invasion along
with three other pathologically determined parameters could be
used to make decisions regarding adjuvant therapy in stage II CRC.
In our study, increased GDF15 expression was negatively
associated with vascular invasion. This observation is supported
by a previous report on the anti-angiogenic activity of GDF15
(Ferrari et al, 2005) in which GDF15 was demonstrated both
in vivo and in vitro to inhibit angiogenesis in endothelial cells. This
inconsistent finding, of decreased vascular invasion and higher
risk for recurrences, could be a result of the increased likelihood of
a significant outcome by chance because of multiple testing;
nevertheless, it could also be explained by the divergent molecular
mechanisms of GDF15. GDF15 has been implicated both as a
promoter and inhibitor of tumour growth (Tan et al, 2000; Baek
et al, 2001; Levy and Hill, 2006; Abd El-Aziz et al, 2007; Johnen
et al, 2007). The conflicting results between in vitro and in vivo
studies regarding the role of GDF15 in tumourigenesis can
probably be attributed to the interaction of the tumour with the
microenvironment (Albertoni et al, 2002; Krieg et al, 2010). The
current belief is that GDF15 has pleiotropic effects in cancer
progression by functioning as a tumour suppressor inhibiting
tumour growth, inducing apoptosis in early stages, although it
promotes proliferation, migration, invasion and metastasis in
more advanced disease stages (Mimeault and Batra, 2010). This
belief of a dual and stage-dependent role of GDF15 in tumouri-
genesis could potentially, in our study, explain why a high
intensity of GDF15 expression was associated with a shorter time
to recurrence in stage III but not in stage II disease.
We confirmed a difference in the intensity of immunoreactivity
of GDF15 between normal mucosa and invasive tumour tissue, but
failed to demonstrate a difference in the fraction of GDF15-positive
cells between normal tissue and invasive tumour tissue. This
indicates that there might be a pathophysiological distinction
between activity of GDF15 expression (measured as intensity) and
actual number of cells expressing GDF15 (measured as fraction)
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Figure 4 GDF15 plasma levels and intensity (A) and fraction (B)o f
immunohistochemistry expression of GDF15 in 57 patients with colorectal
cancer stages I–IV. The boxes represents median and quantiles and bars
minimum and maximum. Circles are outliers with values between 1.5 and 3
box lengths from the upper edge of the box and asterisks are extremes
with values more than 3 box lengths from the upper edge of the box.
Overall survival according to the median GDF15 plasma levels in patients
operated for CRC stages I–IV (n¼57). The multivariate Cox proportional
analyses include gender, hereditary for CRC, N-substage and neural
invasion (C).
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sbetween invasive tumour tissue and normal mucosa, supporting
that intensity of immunoreactivity rather than fraction of positive
cells for GDF15 better serves as a prognostic marker in CRC.
Plasma levels of GDF15 have been studied as a biomarker in
cardiovascular disease (Hochholzer et al, 2010) and elevated levels
have been seen in metastatic CRC, breast and prostate carcinomas
compared with normal controls (Welsh et al, 2003). The
correlation between GDF15 plasma levels and CEA in the whole
cohort including all disease stages was weak, but when analysing
patients with stage IV disease, a stronger correlation was observed.
We demonstrated a gradual trend of increasing GDF15 plasma
levels from stage I to IV, whereas the CEA levels were low in
patients with early disease stages, but significantly elevated in stage
IV patients. The predictive value of CEA for detecting colorectal
cancer in early stages is known to be low (Fletcher, 1986), although
there is clear evidence that preoperative plasma CEA levels
correlate with stage and serve as an independent prognostic factor
of survival (Wanebo et al, 1978; Wolmark et al, 1984; Slentz et al,
1994). Consistent with a previous study by Brown et al (2003),
GDF15 plasma levels in our study was an independent prognostic
factor of survival supporting that measurement of GDF15 levels in
plasma might add additional prognostic information in patients
with CRC. The samples in our study were strategically selected to
get a more reliable estimate the GDF15 plasma analyses but still
limited by the small sample size and, therefore, decreased the
power and the precision of the results.
Other issues regarding immunohistochemistry related to
different fixation techniques and duration of fixation of the
tumour tissue could potentially also have influence our results
(Atkins et al, 2004; Leong, 2004; Paavilainen et al, 2010). However,
in our study all tissue specimens were handled at the same
pathology department. Consequently, in this prospectively
collected material, we predict low variability of the actual handling
of the tissue specimens. The antibody used in the immunohis-
tochemistry staining had a high specificity on protein array and a
single band corresponding to the predicted size in kDa on the
western blot. Therefore, we believe that it is less likely that the
specificity of the antibody influenced our results.
In conclusion, we have demonstrated that increased GDF15
expression may have a negative prognostic value in patients
curatively operated for CRC stages I–III and III disease. However,
the actual role of GDF15 in tumourigenesis is still unclear, and
further research regarding both its pathophysiological role and
clinical use as a prognostic marker for CRC is needed preferably in
prospective clinical trials.
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